Year: 2020

We’re bargain hunting, looking for stocks that will bring strong returns for a low cost of entry. Our criteria, a “Strong Buy” analyst consensus combined with upside potential that exceeds 20%, naturally leads us to the energy sector. Despite high overhead and low prices, oil and gas extraction remain cash-rich niches, with potential for high profits when a company strikes a rich deposit.Using TipRanks’ Stock Screener, we’ve picked out three energy stocks to power up your investment portfolio. All three are priced at a bargain, have Buy ratings from Wall Street’s analysts, and boast superb upside potential. Let’s dive in, …read more […]

A week ago, Microsoft Corporation (NASDAQ:MSFT) came out with a strong set of second-quarter numbers that could… …read more […]

The stock market is unlikely out of hot water when it comes to the realities stemming from the coronavirus. …read more […]

Altria Group, Inc. (NYSE:MO) shares fell 5.4% to US$47.53 in the week since its latest yearly results. Revenues came… …read more […]

Tax anxieties are higher among younger Americans. Fueling those worries are misconceptions that can cost them money. …read more […]

WSJ’s Tim Higgins explores how CEO Elon Musk turned Tesla into the most valuable U.S. auto maker of all time. …read more […]

(Bloomberg) — Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.China has kick-started a clinical trial to speedily test a drug for the novel coronavirus infection as the nation rushes therapies for those afflicted and scours for vaccines to protect the rest.Remdesivir, a new antiviral drug by Gilead Sciences Inc. aimed at infectious diseases such Ebola and SARS, will be tested by a medical team from Beijing-based China-Japan Friendship Hospital for efficacy in treating the deadly new strain of coronavirus, a hospital spokeswoman told Bloomberg News Monday.Trial for the drug will be …read more […]